CVRx, Inc. (CVRX)

NMS – Цена в реальном времени. Валюта: USD

5.27

-1.65 (-23.84%)

При закрытии: May 12, 2026, 4:00 PM EDT

5.40

+0.13 (2.47%)

После закрытия: May 12, 2026, 7:26 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

CVRx, Inc. (CVRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CVRx, Inc. (CVRX)

CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript

CVRx Q1 Earnings Call Highlights

CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

Видео

No Data

Пресс-релизы

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

CVRx, Inc. Investigated by the Portnoy Law Firm

Search stocks

CVRx, Inc. (CVRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CVRx, Inc. (CVRX)

CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript

CVRx Q1 Earnings Call Highlights

CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

Видео

No Data

Пресс-релизы

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

CVRx, Inc. Investigated by the Portnoy Law Firm